Related Articles
Oral low-dose dexamethasone for androgen-independent prostate cancer patients
Low-dose docetaxel, estramustine and prednisolone combination chemotherapy for castration-resistant prostate cancer
A phase II study of bromocriptine in patients with androgen-independent prostate cancer.
Docetaxel chemotherapy for metastatic hormone refractory prostate cancer as first-line palliative chemotherapy and subsequent re-treatment: Birmingham experience
Overexpression of orotate phosphoribosyl transferase in hormone-refractory prostate cancer